from BUSINESS LINE, October 27, 2009 New Delhi, Oct. 26 - Riding on its growth in the emerging markets, Ranbaxy Laboratories Ltd on Monday reported consolidated profits of Rs 116.6 crore for the third quarter ended September 30 compared with a loss of Rs 394.5 crore in the same period last year.
However, a huge dip in US sales pulled down its income by 18 per cent to Rs 1,720.5 crore compared with Rs 1,888.4 crore in the corresponding quarter last year.
On a standalone basis, Ranbaxy reported to the BSE a net profit of Rs 186 crore compared with a loss of Rs 352 crore last year. Standalone income stood at Rs 439 crore in Q3 2009.
Commenting on the results …